|
業務類別
|
Biotechnology |
|
業務概覽
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stagegene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
| 公司地址
| 345 Park Avenue South, Floor 6, New York, NY, USA, 10010 |
| 電話號碼
| +1 212 547-9879 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lexeotx.com |
| 員工數量
| 72 |
| Dr. Sandi See Tai, M.D. |
Chief Development Officer |
-- |
28/04/2025 |
| Mr. Narinder P. Bhalla, M.D. |
Chief Medical Officer |
-- |
27/01/2026 |
| Mr. Louis Tamayo |
Chief Financial Officer and Principal Accounting Officer |
-- |
14/08/2025 |
| Mr. Jose Manuel Otero, PhD |
Chief Operating Officer |
-- |
27/01/2026 |
| Ms. Jenny R. Robertson, J.D. |
Chief Legal Officer |
-- |
28/04/2025 |
| Mr. Richard Nolan Townsend |
Director and Chief Executive Officer |
美元 600.00K |
28/04/2025 |
|
|
| Mr. Tim Van Hauwermeiren, M. Sc. |
Independent Director |
28/04/2025 |
| Mr. Tolga Tanguler |
Independent Director |
28/04/2025 |
| Ms. Paula H.J. Cholmondeley |
Independent Director |
28/04/2025 |
| Dr. Steven Altschuler, M.D. |
Chairman of the Board |
28/04/2025 |
| Ms. Mette Kirstine Agger |
Independent Director |
28/04/2025 |
| Mr. Reinaldo M. Diaz |
Independent Director |
28/04/2025 |
| Dr. Brenda Cooperstone, M.D. |
Independent Director |
28/04/2025 |
| Mr. Richard Nolan Townsend |
Director and Chief Executive Officer |
28/04/2025 |
|
|
|
|
